Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeneFIX in previously treated patients with hemophilia B
NCT00093171Phase 3Completed
- Sponsor
- Pfizer
- Primary completion
- May 2005
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of coagulation factor ix recombinant in hemophilia B (HB), sponsored by Pfizer. Primary endpoint: Incidence of Factor IX inhibitor development at 6 months. Status: completed.
02
Drugs
coagulation factor ix recombinant
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT00093171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093171.